Our Vision

Through innovative sustained-release therapeutics, we aim to resolve the treatment burden of frequent intravitreal injections and improve the quality of care for patients with sight-threatening diseases.

We are developing and delivering photo-crosslinked, biodegradable ocular drug delivery systems engineered to provide 6 months + sustained release for a broad range of therapeutic modalities, including Biologics, Peptides, Large and Small Molecules

Our Technologies

PHOTO-CROSSLINKED, PRE-FABRICATED IMPLANTS ≤2 µg/day for 6 Mo.

EyeLief® & EyeLief-SD™

Pre-fabricated IVT implants photo-crosslinked using UV light, administered in the clinic via narrow gauge needles, designed to deliver a range of therapeutic modalities, including Biologics, Peptides, Large and Small Molecules.

IN SITU PHOTO-CROSSLINKED ≥2 µg/day for 6-12 Mo.

OcuLief®

In situ fabricated IVT implants, photo-crosslinked using visible light, administered in the clinic via narrow gauge needles and a bespoke applicator, delivering high doses as a liquid that cures into a solid implant for controlled, sustained release of a range of therapeutic modalities, including Biologics, Peptides, Large and Small Molecules.

Our Strategies

Solving the No. 1 Unmet Need

Reducing the frequent injection burden of anti VEGF’s, Biologics, Peptides, Large and Small Molecules

Breakthrough in Biologic Delivery

Photo-crosslinked biodegradable hydrogel: protects and preserves Biologics ensuring customizable tunable release with proven tolerability (avoids common cause of inflammation)

1st In-Clinic Technology

Potential to deliver 0.05 µg/day to 20 µg/day for up to 12 months

Strategic Collaborations

Active partnerships with leading global pharmaceutical companies including Boehringer Ingelheim

Partnerships and Collaborations

Re-Vana is working with several global pharmaceutical companies in conducting preformulation and preclinical feasibility studies.

Find Out More